Tuesday, September 22, 2009
Sleep Hygiene
Sunday, September 20, 2009
Breast Cancer Symposium - 16 Sept 2009
Breast Cancer Symposium For Primary Care Providers – 16 Sept 2009
Presenters: CDR Henry, MC, USN & Anne Forsha, RN
Basics
Value of early detection
90% survival rate (5 yrs) if caught in a localized state
59% survival rate (5 yrs) if spread to regional lymph nodes
Tamoxifen
If taken for 5 yrs, a 49-88% reduction in risk of estrogen receptor-positive tumors
Fisher B, et al. Tamoxifen for prevention of breast cancer: report of the P-1 study. J Natl Cancer Inst 90:1271, 1998
Raloxifene has lower incidence rates for uterine hyperplasia but this can only be taken by post-menopausal women
6 Dangerous Lies About Breast Cancer
You’re too young to have breast cancer
Cancer dosen’t hurt
Cancer presents as pain in 5% of patients
Negative Mammograms rule out breast cancer
False negatives ~20%
~ 20% of breast cancers are ONLY detected by clinical breast exam
No family history means you are safe
80% of breast cancer patients have NO RISK FACTORS (besides gender)
Men can’t get breast cancer
1% of breast cancers are in men
It’s just mastitis
Diagnostic Imaging
Resolution for MRI ~ 5mm & mammogram ~ 1cm
No evidence to suggest difference in care between these two
Hormone Receptors
Estrogen & Progesterone are primary players
~ 80% of breast cancers are + for hormone receptors
This determines treatment, prevention, & prognosis
Clinical Breast Exam
Start with patient seated and observe for change in size, shape, dimpling, erythema, nipple discharge, nipple retraction
Acronym: B.R.E.A.S.T. – Breast mass, Retraction, Edema, Axillary mass, Scaly nipple, Tender breast
Have pt raise arms over head and observe for skin retraction
Have pt supine with ipsilateral arm over her head & palpate with pads of first 3 fingers
Be sure to include entire area from clavicle to inframammary ridge and from the latissimus dorsi to the sternum
Best time for the exam is just after menses before the spike in progesterone mid cycle when breast gets firmer
Should be performed every 3 yrs from age 25 – 39 and annually from age 40 on
Nipple Discharge
Seen with 3% of breast cancers
Green = OK (probably fibrocystic dz)
Watery/Serous = Bad
Bloody/Serosang = Bad
Spontaneous = Bad
Only one duct = Bad
Estrogen
Study with Prempro (conjugated estrogen & progesterone used to treat symptoms of menopause) Jama 289(24):3304, 2003
16,608 women ages 58-79
Prempro vs placebo
Prempro group
26% increase in breast cancer
22% increase in cardiovascular events
24% decrease in hip fractures
37% decrease in colorectal cancer
Hormone replacement therapy risks are far greater than benefits
Risk Assessment
Hereditary susceptibility
BRCA1 gene: 20% - 40% contribution to hereditary breast cancer
BRCA2 gene: 10% - 30% contribution to hereditary breast cancer
Features indicating increased likelihood of BRCA mutation
Multiple cases of early onset breast cancer
Ovarian cancer (with family history of breast or ovarian cancer)
Breast and ovarian cancer in the same woman
Bilateral breast cancer
Ashkenazi Jewish heritage
Male breast cancer
Risk of breast cancer
General population: by age 50 – 2%, by age 80 – 10%
In mutation carriers: by age 50 – 73% by age 80 – 87%
Who should get genetic testing
Pt with breast or ovarian cancer that was diagnosed at a young age or has a strong family history of breast or ovarian cancer
Lifestyle & Risk
Weight – no clear association
Exercise – no clear association
Alcohol – >2 drinks per day is associated with an increased risk of breast cancer
Tobacco – no clear association
Stress – no clear association
Oral Contraceptives – very little risk for women under 40 yrs